Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,082.10 | 68.80 | 0.86% |
CAC 40 | 8,073.98 | 45.70 | 0.57% |
DAX 40 | 23,154.57 | 167.75 | 0.73% |
Dow JONES (US) | 41,747.61 | 259.42 | 0.63% |
FTSE 100 | 8,680.29 | 47.96 | 0.56% |
HKSE | 24,145.57 | 185.59 | 0.77% |
NASDAQ | 17,708.20 | 45.89 | -0.26% |
Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
NZX 50 Index | 12,166.14 | 100.11 | -0.82% |
S&P 500 | 5,654.55 | 15.61 | 0.28% |
S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
SSE Composite Index | 3,426.13 | 6.57 | 0.19% |